PF 06760805

Drug Profile

PF 06760805

Alternative Names: GBS infection vaccine - Pfizer; Multivalent Group B Streptococcus vaccine - Pfizer; PF-06760805

Latest Information Update: 29 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Pfizer
  • Class Antibacterials; Streptococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Streptococcal infections

Most Recent Events

  • 19 Jun 2017 Phase-I/II clinical trials in Streptococcal infections (Prevention) in USA (IM)
  • 19 Oct 2016 Preclinical trials in Streptococcal infections (Prevention) in USA (Parenteral) before October 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top